Modulation of visceral hyperalgesia by morphine and cholecystokinin from the rat rostroventral medial medulla

[1]  A. Dickenson,et al.  Spinal opioid systems in inflammation , 1995, Inflammation Research.

[2]  P. Mason,et al.  Raphe magnus neurons respond to noxious colorectal distension. , 2003, Journal of neurophysiology.

[3]  G. Gebhart,et al.  Chronic pain and medullary descending facilitation , 2002, Trends in Neurosciences.

[4]  R. Dubner,et al.  Plasticity in excitatory amino acid receptor-mediated descending pain modulation after inflammation. , 2002, The Journal of pharmacology and experimental therapeutics.

[5]  R. Dubner,et al.  Changes in gene expression and neuronal phenotype in brain stem pain modulatory circuitry after inflammation. , 2002, Journal of neurophysiology.

[6]  Xiao-jun Xu,et al.  Increased level of cholecystokinin in cerebrospinal fluid is associated with chronic pain-like behavior in spinally injured rats , 2001, Peptides.

[7]  K. Sluka,et al.  Blockade of opioid receptors in rostral ventral medulla prevents antihyperalgesia produced by transcutaneous electrical nerve stimulation (TENS). , 2001, The Journal of pharmacology and experimental therapeutics.

[8]  M. Heinricher,et al.  Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. , 2001, Journal of neurophysiology.

[9]  P. Mason,et al.  Contributions of the medullary raphe and ventromedial reticular region to pain modulation and other homeostatic functions. , 2001, Annual review of neuroscience.

[10]  F. Porreca,et al.  Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat , 2000, Pain.

[11]  P. Mantyh,et al.  Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons , 2000, Neuroscience.

[12]  G. Gebhart,et al.  Effects of spinal cholecystokinin receptor antagonists on morphine antinociception in a model of visceral pain in the rat. , 2000, The Journal of pharmacology and experimental therapeutics.

[13]  R. Hurley,et al.  The Analgesic Effects of Supraspinal μ and δ Opioid Receptor Agonists Are Potentiated during Persistent Inflammation , 2000, The Journal of Neuroscience.

[14]  R. Hurley,et al.  The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  T. Hökfelt,et al.  Cholecystokinin/opioid interactions , 1999, Brain Research.

[16]  T. Hökfelt,et al.  Effect of morphine on cholecystokinin and μ-opioid receptor-like immunoreactivities in rat spinal dorsal horn neurons after peripheral axotomy and inflammation , 1999, Neuroscience.

[17]  M. Urban,et al.  Supraspinal contributions to hyperalgesia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  David J. Smith,et al.  Stress reduces morphine's antinociceptive potency: dependence upon spinal cholecystokinin processes , 1999, Brain Research.

[19]  A. Basbaum.  Opioids in Pain Control , 1999, Nature Medicine.

[20]  A. Basbaum.  Spinal mechanisms of acute and persistent pain. , 1999, Regional anesthesia and pain medicine.

[21]  P. Cabot,et al.  Opioids in Pain Control: Peripheral Opioid Analgesia: Mechanisms and Clinical Implications , 1998 .

[22]  M. Urban,et al.  Role of glutamate receptors and nitric oxide in the rostral ventromedial medulla in visceral hyperalgesia , 1998, Pain.

[23]  H. Fields,et al.  The contribution of the rostral ventromedial medulla to the antinociceptive effects of systemic morphine in restrained and unrestrained rats , 1998, Neuroscience.

[24]  Z. Wiesenfeld‐Hallin,et al.  Differential release of cholecystokinin by morphine in rat spinal cord , 1998, Neuroscience Letters.

[25]  P. Beart,et al.  Histochemistry in rat brain and spinal cord with an antibody directed at the cholecystokininA receptor , 1997, Neuroscience Letters.

[26]  T. Gaginella.  Handbook of methods in gastrointestinal pharmacology , 1996 .

[27]  P. Law,et al.  Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  J. Stamford.  Descending control of pain. , 1995, British journal of anaesthesia.

[29]  Jacqueline N. Crawley,et al.  Biological actions of cholecystokinin , 1994, Peptides.

[30]  T. Hökfelt,et al.  Messenger plasticity in primary sensory neurons following axotomy and its functional implications , 1994, Trends in Neurosciences.

[31]  M. Fournié-Zaluski,et al.  Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. , 1994, The Journal of pharmacology and experimental therapeutics.

[32]  Xiao-jun Xu,et al.  Cholecystokinin and morphine analgesia: variations on a theme. , 1994, Trends in pharmacological sciences.

[33]  J. Han,et al.  Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord. , 1993, European journal of pharmacology.

[34]  T. Hökfelt,et al.  Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat , 1993, Neuroscience Letters.

[35]  A. Dickenson,et al.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation , 1993, British journal of pharmacology.

[36]  L. Tseng,et al.  Cholecystokinin administered intrathecally selectively antagonizes intracerebroventricular beta-endorphin-induced tail-flick inhibition in the mouse. , 1992, The Journal of pharmacology and experimental therapeutics.

[37]  L. Tseng,et al.  Intrathecal cholecystokinin octapeptide attenuates the antinociception and release of immunoreactive Met-enkephalin induced by intraventricular β-endorphin in the rat , 1992, Neuropeptides.

[38]  R. Dubner,et al.  Preproenkephalin mrna in spinal dorsal horn neurons is induced by peripheral inflammation and is co-localized with Fos and Fos-related proteins , 1992, Neuroscience.

[39]  A. Randich,et al.  Further behavioral evidence that colorectal distension is a ‘noxious’ visceral stimulus in rats , 1991, Neuroscience Letters.

[40]  G. Woodruff,et al.  Functional role of brain CCK receptors , 1991, Neuropeptides.

[41]  M. Hamon,et al.  Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation , 1991, Neuroscience Letters.

[42]  D. Price,et al.  Cholecystokinin and its antagonist lorglumide respectively attenuate and facilitate morphine-induced inhibition of C-fiber evoked discharges of dorsal horn nociceptive neurons , 1991, Brain Research.

[43]  M. Hamon,et al.  Differential inhibitory/stimulatory modulation of spinal CCK release by mu and delta opioid agonists, and selective blockade of mu-dependent inhibition by kappa receptor stimulation. , 1991, Neuroscience Letters.

[44]  L. Tseng,et al.  Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice. , 1990, European journal of pharmacology.

[45]  N. Baber,et al.  The role of CCK, caerulein, and CCK antagonists in nociception , 1989, Pain.

[46]  M. Iadarola,et al.  Temporal analysis of increases in c-fos, preprodynorphin and preproenkephalin mRNAs in rat spinal cord. , 1989, Brain research. Molecular brain research.

[47]  S. Iversen,et al.  Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329 , 1989, Neuropharmacology.

[48]  J. Wallace,et al.  Hapten-induced model of chronic inflammation and ulceration in the rat colon. , 1989, Gastroenterology.

[49]  R. Dubner,et al.  Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding , 1988, Pain.

[50]  R. M. Bowker,et al.  Distribution of μ-opioid receptors in the nucleus raphe magnus and nucleus gigantocellularis: A quantitative autoradiographic study , 1988, Neuroscience Letters.

[51]  T. Ness,et al.  Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat , 1988, Brain Research.

[52]  R. M. Bowker,et al.  Distribution of mu-opioid receptors in the nucleus raphe magnus and nucleus gigantocellularis: a quantitative autoradiographic study. , 1988, Neuroscience letters.

[53]  M. Iadarola,et al.  In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal dynorphin biosynthesis in a rat model of peripheral inflammation and hyperalgesia. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[54]  C. Dourish,et al.  Classification and function of CCK receptors , 1987 .

[55]  Z. Wiesenfeld‐Hallin,et al.  Intrathecal cholecystokinin interacts with morphine but not substance P in modulating the nociceptive flexion reflex in the rat , 1987, Peptides.

[56]  J. Lauterborn,et al.  Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain , 1987, Brain Research.

[57]  T. Jensen,et al.  I. Comparison of antinociceptive action of morphine in the periaqueductal gray, medial and paramedial medulla in rat , 1986, Brain Research.

[58]  Paul R. McHugh,et al.  Two brain cholecystokinin receptors: implications for behavioral actions , 1986, Brain Research.

[59]  L. Watkins,et al.  Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide , 1985, Brain Research.

[60]  L. Watkins,et al.  Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates , 1985, Brain Research.

[61]  M. Iadarola,et al.  Proglumide prevents and curtails acute tolerance to morphine in rats , 1984, Neuropharmacology.

[62]  L. Watkins,et al.  Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. , 1984, Science.

[63]  P. Mantyh,et al.  Evidence for cholecystokinin-like immunoreactive neurons in the rat medulla oblongata which project to the spinal cord , 1984, Brain Research.

[64]  L. Watkins,et al.  Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. , 1983, Science.

[65]  S. Itoh,et al.  Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat , 1982 .

[66]  S. Itoh,et al.  Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. , 1982, European journal of pharmacology.

[67]  K. Stengaard-Pedersen,et al.  Localization and opiate receptor binding of enkephalin, CCK and ACTH/β-endorphin in the rat central nervous system , 1981, Peptides.

[68]  S. Snyder,et al.  Distinct cholecystokinin receptors in brain and pancreas. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[69]  I. Goldfine,et al.  Cholecystokinin receptors in the brain: characterization and distribution. , 1980, Science.

[70]  J. Besson,et al.  Role of the nucleus raphe magnus in opiate analgesia as studied by the microinjection technique in the rat , 1979, Brain Research.

[71]  G. Dockray,et al.  Immunochemical evidence of cholecystokinin-like peptides in brain , 1976, Nature.

[72]  J. Mackenzie.  Symptoms and Their Interpretation , 1912, The Indian Medical Gazette.